Strong Q4 Revenue Growth
Total revenue of $12.0M in Q4 2025, up 70.2% year-over-year from $7.0M and up from $9.3M in Q3 2025; full year 2025 revenue exceeded the high end of prior guidance ($30M–$32M).
Record Gross Margin Expansion
Record quarterly gross margin of 58.5% in Q4 2025 versus 9.4% in the prior-year quarter (26.8% ex the prior-year $1.2M contract loss). The year-over-year margin increase was 31.7 percentage points, driven by favorable product mix, pricing, and operational efficiency.
Return to Profitability and Strong Non-GAAP Results
GAAP net income from continuing operations of $2.0M ($0.08 per diluted share) in Q4 2025 versus a $3.4M loss in prior-year quarter; non-GAAP net income from continuing operations of $2.4M ($0.09 per diluted share). Adjusted EBITDA from continuing operations was $2.5M vs an adjusted EBITDA loss of $2.8M in prior-year Q4.
Material Balance Sheet Strengthening
Sale of Bressner produced proceeds of $22.4M; cash, cash equivalents, and restricted cash totaled $33.4M ($31.2M cash + $2.2M restricted); no debt outstanding; total liabilities of $6.8M and working capital of $45.3M (improved from $24.0M prior year).
Robust Book-to-Bill and Backlog Visibility
Book-to-bill of approximately 1.2x in 2025, indicating continued demand and pipeline momentum and providing greater visibility into multiyear program revenue streams.
Significant Defense Program Wins and Pipeline
Secured over $65M in total contracted revenue tied to the P-8 program (including $23M awarded in 2025 and a recent $10.5M award). Received a $1.2M follow-on order from Safran (aggregate ~$1.9M) with an expectation of >$7M cumulative production orders over 5 years. New agreements for Army vehicle enhanced vision and continued 360-degree situational awareness testing expand defense footprint.
Growing Commercial Wins with Multiyear Potential
Commercial robotics engagement won by displacing incumbent; $1.5M initial aerospace order expected to generate ~$6M over 3 years; $2.0M follow-on medical imaging order expected to generate >$25M cumulative revenue over 5 years as programs move into volume production.
Positive 2026 Guidance and Strategic Positioning
2026 guidance calling for 20%–25% revenue growth, ~40% gross margins, and positive EBITDA/adjusted EBITDA; strategic repositioning as a pure-play ruggedized AI/edge compute provider and expressed capacity to pursue strategic M&A to accelerate growth.